KORI JUBAN: Open Payments
NPI 1346761301 · WALKER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,296 in 105 payments from 19 companies in 2025. Trend: 2023 $1,964 · 2024 $1,678 · 2025 $2,296
Food & beverage: $2,296
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $279 |
| PFIZER INC. | 13 | $275 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $274 |
| Lilly USA, LLC | 17 | $263 |
| Novo Nordisk Inc | 9 | $233 |
| GlaxoSmithKline, LLC. | 13 | $220 |
| Axsome Therapeutics, Inc. | 4 | $193 |
| AstraZeneca Pharmaceuticals LP | 9 | $164 |
| Collegium Pharmaceutical, Inc. | 1 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
Products named: Kerendia, Auvelity, TRELEGY ELLIPTA, VRAYLAR, Ozempic, PREVNAR 20, MOUNJARO, QULIPTA.
Industry payments across LA — which companies pay providers there.
